Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Loratadine

FDA-approved product (tablet, oral), marketed as Alavert, Children's Claritin, Claritin and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Loratadine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Allergic rhinitis
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antihistamines for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Loratadine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Loratadine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

    NCT07661459 · start 2026-06-26

    Registered record
    Registry ID
    NCT07661459
    Conditions
    Solid Tumors
    Interventions
    Asprin; Loratadine; Acetaminophen Avoidance; THC Avoidance
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-26
    Completion
    2027-07-31
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionAsprin; Loratadine; Acetaminophen Avoidance; THC Avoidance
    PhasePhase 2
    Registry statusRecruiting

  • The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis

    NCT07380178 · start 2025-04-01

    Registered record
    Registry ID
    NCT07380178
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Quercetin; Apple Extract; Loratadine 10 Mg; Fluticasone Furoate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-04-01
    Completion
    2025-07-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionQuercetin; Apple Extract; Loratadine 10 Mg; Fluticasone Furoate
    PhaseNot applicable
    Registry statusCompleted

  • Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers

    NCT07300735 · start 2025-03-01

    Registered record
    Registry ID
    NCT07300735
    Conditions
    Hematologic Malignancy; Neutropenia; Bone Pain
    Interventions
    Loratadine; Diosmin-Hesperidin; Loratadine + Diosmin-Hesperidin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-03-01
    Completion
    2027-07
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancy; Neutropenia; Bone Pain
    InterventionLoratadine; Diosmin-Hesperidin; Loratadine + Diosmin-Hesperidin
    PhaseNot applicable
    Registry statusRecruiting

  • Loratadine for the Prevention of G-CSF-related Bone Pain

    NCT05421416 · start 2024-11-28

    Registered record
    Registry ID
    NCT05421416
    Conditions
    Stem Cell Transplant Complications
    Interventions
    Loratadine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-28
    Completion
    2026-12-01
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStem Cell Transplant Complications
    InterventionLoratadine; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome.

    NCT06396013 · start 2024-06-01

    Registered record
    Registry ID
    NCT06396013
    Conditions
    Plaque Psoriasis
    Interventions
    Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-06-01
    Completion
    2026-07-31
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionChitosan Nanocrystalline Qinteng Huoxue Runji Ointment; placebo
    PhasePhase 1
    Registry statusUnknown

  • Over-the-Counter Antihistamines & Heat Stress

    NCT06217367 · start 2023-12-05

    Registered record
    Registry ID
    NCT06217367
    Conditions
    Heat Illness; Allergic Rhinitis; Heat Injury; Sudomotor Sympathetic Dysfunction
    Interventions
    50 mg Diphenhydramine; 10 mg Loratadine; 5 mg Desloratadine; Placebo (Sugar Pill)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-12-05
    Completion
    2024-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeat Illness; Allergic Rhinitis; Heat Injury; Sudomotor Sympathetic Dysfunction
    Intervention50 mg Diphenhydramine; 10 mg Loratadine; 5 mg Desloratadine; Placebo (Sugar Pill)
    PhasePhase 4
    Registry statusUnknown

  • A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

    NCT06019728 · start 2023-11-10

    Registered record
    Registry ID
    NCT06019728
    Conditions
    Fabry's Disease
    Interventions
    AGALSIDASE BETA (GZ419828); Acetaminophen; Diphenhydramine; Dexamethasone; Montelukast; Loratadine; Cetirizine; Fexofenadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-11-10
    Completion
    2024-10-25
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFabry's Disease
    InterventionAGALSIDASE BETA (GZ419828); Acetaminophen; Diphenhydramine; Dexamethasone +4 more
    PhasePhase 4
    Registry statusCompleted

  • Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

    NCT04211259 · start 2022-04-18

    Registered record
    Registry ID
    NCT04211259
    Conditions
    Plasma Cell Myeloma
    Interventions
    Loratadine; Placebo; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2022-04-18
    Completion
    2027-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasma Cell Myeloma
    InterventionLoratadine; Placebo; Questionnaire Administration
    PhaseEarly phase 1
    Registry statusRecruiting

  • Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients

    NCT05275933 · start 2022-04-05

    Registered record
    Registry ID
    NCT05275933
    Conditions
    COVID-19
    Interventions
    TCM intervention; Placebo intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-04-05
    Completion
    2023-11-22
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionTCM intervention; Placebo intervention
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

    NCT05263206 · start 2022-02-15

    Registered record
    Registry ID
    NCT05263206
    Conditions
    Pruritus
    Interventions
    Dupilumab; Placebo; Fexofenadine (loratadine if not available)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-02-15
    Completion
    2027-08-25
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPruritus
    InterventionDupilumab; Placebo; Fexofenadine (loratadine if not available)
    PhasePhase 3
    Registry statusRecruiting

  • Effect of Loratadine in Lymphangioleiomyomatosis

    NCT05190627 · start 2021-11-01

    Registered record
    Registry ID
    NCT05190627
    Conditions
    Lymphangioleiomyomatosis
    Interventions
    Loratadine; Placebo 10mg/day added to rapamycin for 12 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-11-01
    Completion
    2023-12-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis
    InterventionLoratadine; Placebo 10mg/day added to rapamycin for 12 months
    PhasePhase 2
    Registry statusUnknown

  • Combined Antihistaminics Therapy in COVID 19 Patients

    NCT05043350 · start 2021-09-13

    Registered record
    Registry ID
    NCT05043350
    Conditions
    Covid19
    Interventions
    Loratadine; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-09-13
    Completion
    2022-07-30
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionLoratadine; Famotidine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Antihistamines in Eosinophilic Esophagitis

    NCT04248712 · start 2020-07-10

    Registered record
    Registry ID
    NCT04248712
    Conditions
    Eosinophilic Esophagitis
    Interventions
    Famotidine; Loratadine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-07-10
    Completion
    2021-12-31
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Esophagitis
    InterventionFamotidine; Loratadine; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

    NCT03883386 · start 2019-06-24

    Registered record
    Registry ID
    NCT03883386
    Conditions
    Bone Pain
    Interventions
    Loratadine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-06-24
    Completion
    2019-10-18
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Pain
    InterventionLoratadine; Placebo
    PhasePhase 2
    Registry statusTerminated

  • A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

    NCT03517930 · start 2018-04-17

    Registered record
    Registry ID
    NCT03517930
    Conditions
    Clinical Pharmacology
    Interventions
    Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG); Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-17
    Completion
    2018-07-20
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Pharmacology
    InterventionLoratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG); Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
    PhasePhase 1
    Registry statusCompleted